Show simple item record

dc.rights.licenseopenen_US
dc.contributor.authorZIAD, Abdelkrim
dc.contributor.authorBERR, Claudine
dc.contributor.authorRUIZ, Fabrice
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEGAUD, Bernard
dc.contributor.authorLEMOGNE, Cédric
dc.contributor.authorGOLDBERG, Marcel
dc.contributor.authorZINS, Marie
dc.contributor.authorMURA, Thibault
dc.date.accessioned2021-03-30T11:42:48Z
dc.date.available2021-03-30T11:42:48Z
dc.date.issued2021-02-11
dc.identifier.issn0114-5916en_US
dc.identifier.urioai:crossref.org:10.1007/s40264-021-01043-5
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26827
dc.description.abstractEnINTRODUCTION: Psychotropic drugs such as anxiolytics, antidepressants and antipsychotics may have anticholinergic properties that could directly affect patients' cognition. OBJECTIVES: Our objective was to assess the relationship between exposure to anticholinergic-positive (AC+) psychotropic drugs and cognitive impairment compared with psychotropic drugs without anticholinergic activity (AC-). METHODS: This analysis included participants (aged 45-70 years) enrolled between January 2012 and October 2017 in the CONSTANCES cohort treated with psychotropic drugs (antidepressants n = 2602, anxiolytics n = 1195, antipsychotics n = 197) in the 3 years preceding cognitive assessment. Within each drug class, the Anticholinergic Cognitive Burden scale was used to classify drugs as either AC+ or AC-. Cognitive impairment was defined as a score below - 1 standard deviation from the standardized mean of the neuropsychological score. We used multiple logistic regression models and matching on propensity score to estimate the relationship between anticholinergic activity and cognitive impairment. RESULTS: Our analyses did not show any increased risk of cognitive impairment for AC+ antidepressants and anxiolytics, with the exception of a slight increase for AC+ antidepressants in episodic memory (odds ratio [OR] 1.19; 95% confidence interval [CI] 1.05-1.36). Conversely, we found a more marked increase in risk with AC+ antipsychotics on executive function (Trail Making Test-A [TMT-A], OR 4.49 [95% CI 2.59-7.97] and TMT-B, OR 3.62 [95% CI 2.25-5.89]). CONCLUSION: Our results suggest there is no clinically relevant association between the anticholinergic activity of antidepressant and anxiolytic drugs and cognitive impairment in middle-aged adults. An association could exist between AC+ antipsychotics and executive function.
dc.description.sponsorshipLa cohorte CONSTANCES - Infrastructure épidémiologique ouverte pour la recherche et la surveillanceen_US
dc.language.isoENen_US
dc.sourcecrossref
dc.title.enAnticholinergic Activity of Psychotropic Drugs and Cognitive Impairment Among Participants Aged 45 and Over: The CONSTANCES Study
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s40264-021-01043-5en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33575980en_US
bordeaux.journalDrug Safetyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDMSD Franceen_US
bordeaux.identifier.funderIDAstraZenecaen_US
bordeaux.import.sourcedissemin
hal.identifierhal-03185524
hal.version1
hal.date.transferred2021-03-30T11:42:51Z
hal.exporttrue
workflow.import.sourcedissemin
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Drug%20Safety&rft.date=2021-02-11&rft.eissn=0114-5916&rft.issn=0114-5916&rft.au=ZIAD,%20Abdelkrim&BERR,%20Claudine&RUIZ,%20Fabrice&BEGAUD,%20Bernard&LEMOGNE,%20C%C3%A9dric&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record